Bisphosphonates and Osteonecrosis: Potential Treatment or Serious Complication?

Orthopedic Clinics of North America

Volumn 40, Issue 2, 2009, Pages 223-234

  Goytia, Robin N ^a   Salama, Andrew ^b   Khanuja, Harpal S ^a  

^a GOOD SAMARITAN HOSPITAL   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Avascular necrosis; Bisphosphonates; BRONJ; Osteonecrosis; Osteonecrosis of the femoral head; Osteonecrosis of the jaw

Indexed keywords

ALENDRONIC ACID; ALENDRONIC ACID PLUS COLECALCIFEROL; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; LORON; MOUTHWASH; NERIDRONIC ACID; PAMIDRONIC ACID; PENICILLIN G; PLACEBO; RISEDRONIC ACID; STEROID; THALIDOMIDE; TILUDRONIC ACID; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

BISPHOSPHONATE RELATED OSTEONECROSIS OF THE JAW; BONE NECROSIS; BONE PAIN; CLINICAL FEATURE; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG ERUPTION; DRUG FEVER; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; ESOPHAGUS ULCER; FEMUR HEAD NECROSIS; GASTROINTESTINAL IRRITATION; HEART ATRIUM FIBRILLATION; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; JAW OSTEONECROSIS; LEUKOPENIA; LOW DRUG DOSE; MANDIBLE RECONSTRUCTION; MULTIPLE CYCLE TREATMENT; NONHUMAN; OFF LABEL DRUG USE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT INDICATION;

BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; DIPHOSPHONATES; HUMANS; OSTEONECROSIS; RISK FACTORS;

EID: 63749092515     PISSN: 00305898     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ocl.2008.12.002     Document Type: Review

References (52)

1. Cole Z., Dennison E., and Cooper C. Update on the treatment of post-menopausal osteoporosis. Br Med Bull 86 (2008) 129-143 [epub 2008 May 12]
2. Health, IMS. (2006). "National Prescription Audit Plus™."
3. Morris C.D., and Einhorn T.A. Bisphosphonates in orthopaedic surgery. [review]. J Bone Joint Surg Am 87 7 (2005) 1609-1618
4. Luckman S.P., Hughes D.E., Coxon F.P., et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13 (1998) 581-589
5. Zhang D., Udagawa N., Nakamura I., et al. The small GTP-binding protein, rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts. J Cell Sci 108 (1995) 2285-2292
6. Fisher J.E., Rogers M.J., Halasy J.M., et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96 (1999) 133-138
7. Tonino R.P., Meunier P.J., Emkey R., et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 85 9 (2000) 3109-3115
8. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 (1996) 1535-1541
9. Bauer D.C., Black D.M., Garnero P., et al., Fracture Intervention Trial Study Group. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19 (2004) 1250-1258
10. Bone H.G., Hosking D., Devogelaer J.P., et al., Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 (2004) 1189-1199
11. Rizzoli R., Greenspan S.L., Bone III G., et al., Alendronate Once-Weekly Study Group. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 17 (2002) 1988-1996
12. Siris E., Weinstein R.S., Altman R., et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 81 (1996) 961-967
13. Siris E.S., Chines A.A., Altman R.D., et al. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J Bone Miner Res 13 (1998) 1032-1038
14. McClung M.R., Tou C.K., Goldstein N.H., et al. Tiludronate therapy for Paget's disease of bone. Bone 17 Suppl 5 (1995) 493S-496S [Erratum appears in Bone 1996;18: 292]
15. Green J.R. Antitumor effects of bisphosphonates. Cancer 97 Suppl 3 (2003) 840-847
16. Major P., Lortholary A., Hon J., et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19 (2001) 558-567
17. Heckbert S.R., Li G., Cummings S.R., et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 168 8 (2008) 826-831
18. Mashiba T., Hirano T., Turner C.H., et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15 (2000) 613-620
19. Neviaser A.S., Lane J.M., Lenart B.A., et al. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22 5 (2008) 346-350
20. Mont M.A., Jones L.C., and Hungerford D.S. Nontraumatic osteonecrosis of the femoral head: ten years later. J Bone Joint Surg Am 88 5 (2006) 1117-1132 [review]
21. Glimcher M.J., and Kenzora J.E. Nicolas Andry award. The biology of osteonecrosis of the human femoral head and its clinical implications: 1. Tissue biology. Clin Orthop Relat Res 138 (1979) 284-309
22. Tägil M., Aspenberg P., and Astrand J. Systemic zoledronate precoating of a bone graft reduces bone resorption during remodeling. Acta Orthop 77 1 (2006) 23-26
23. Astrand J., and Aspenberg P. Topical, single dose bisphosphonate treatment reduced bone resorption in a rat model for prosthetic loosening. J Orthop Res 22 2 (2004) 244-249
24. Little D.G., Peat R.A., Mcevoy A., et al. Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats. J Bone Miner Res 18 (2003) 2016-2022
25. Kim H., Randall T.S., Bian H., et al. Ibandronate decreases femoral head deformity following ischemic necrosis of the capital femoral epiphysis in immature pigs. Trans Annu Meet Orthop Res Soc 29 (2004) 151
26. Bowers J.R., Dailiana Z.H., McCarthy E.F., et al. Drug therapy increases bone density in osteonecrosis of the femoral head in canines. J Surg Orthop Adv 13 4 (2004) 210-216
27. Agarwala S., Jain D., Joshi V.R., et al. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip: a prospective open-label study. Rheumatology (Oxford) 44 3 (2005) 352-359 [epub 2004 Nov 30] [Erratum appears in Rheumatology (Oxford) 2005;44(4):569]
28. Lai K.A., Shen W.J., Yang C.Y., et al. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis: a randomized clinical study. J Bone Joint Surg Am 87 10 (2005) 2155-2159
29. Nishii T., Sugano N., Miki H., et al. Does alendronate prevent collapse in osteonecrosis of the femoral head?. Clin Orthop Relat Res 443 (2006) 273-279
30. Ramachandran M., Ward K., Brown R.R., et al. Intravenous bisphosphonate therapy for traumatic osteonecrosis of the femoral head in adolescents. J Bone Joint Surg Am 89 8 (2007) 1727-1734
31. Bedwinek J.M., Shukovsky L.J., Fletcher G.H., et al. Osteonecrosis in patients treated with definitive radiotherapy for squamous cell carcinomas of the oral cavity and naso- and oropharynx. Radiology 119 3 (1976) 665-667
32. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22 10 (2007) 1479-1491
33. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 9 (2003) 1115-1117
34. American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65 3 (2007) 369-376
35. Ruggiero S.L., Mehrotra B., Rosenberg T.J., et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 5 (2004) 527-534
36. Bamias A., Kastritis E., Bamia C., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23 34 (2005) 8580-8587
37. Ezra A., and Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 42 3 (2000) 175-195
38. Durie B.G., Katz M., Crowley J., et al. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353 1 (2005) 99-102 [discussion: 99-102]
39. Sarin J., DeRossi S.S., Akintoye S.O., et al. Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 14 3 (2008) 277-285
40. Mavrokokki T., Cheng A., Stein B., et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65 3 (2007) 415-423
41. Marx R.E., Sawatari Y., Fortin M., et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 11 (2005) 1567-1575
42. Raje N., Woo S.B., Hande K., et al. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res 14 8 (2008) 2387-2395
43. Badros A., Weikel D., Salama A., et al. Osteonecrosis of the jaws in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24 (2006) 945-952
44. Hoff A.O., Toth B.B., Altundag K., et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23 6 (2008) 826-836
45. Brown J.J., Ramalingam L., Zacharin M.R., et al. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?. Clin Endocrinol (Oxf) 68 6 (2008) 863-867
46. Wessel J.H., Dodson T.B., Zavras A.I., et al. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 66 4 (2008) 625-631
47. Hess L.M., Jeter J.M., Benham-Hutchins M., et al. Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med 121 6 (2008) 475-483 [e3]
48. Marx R.E., Cillo Jr. J.E., Ulloa J.J., et al. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65 12 (2007) 2397-2410
49. Santini D., Vespasiani Gentilucci U., Vincenzi B., et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 14 10 (2003) 1468-1476
50. Ferretti G., Fabi A., Carlini P., et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 69 1 (2005) 35-43
51. Diego R., D'Orto O., Pagani D., et al. Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103 3 (2007) e1-e5
52. Engroff S.L., and Kim D.D. Treating bisphosphonate osteonecrosis of the jaws: is there a role for resection and vascularized reconstruction?. J Oral Maxillofac Surg 65 11 (2007) 2374-2385